PAPER Salvatore MF
SEARCH RESULTS
329940 RESULTS
PAPER Seet RC, Lim EC, Tan JJ, Quek A, Chow A, Chong WL, Ng M, Ong CN, Halliwell B
Effects of high-dose coenzyme Q10 on biomarkers of oxidative damage and clinical outcomes in Parkinson disease.
Antioxid Redox Signal. 2014 Jan 11; PubMed: 24410614Yan-Jiang Wang
Daping Hospital, Third Military Medical UniversityChongqing, China
Ben Barres on Brain Shuttle Ferries Antibodies Across the Blood-Brain Barrier
COMMENT Niewoehner and colleagues set out to further improve approaches around targeting the transferrin receptor (TfR) for brain uptake of antibodies. This study is similar to those published by others, however, it further advances the possibilities by engineeri
Dario Alessi on Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.
COMMENT This is an intriguing study. LRRK2 belongs to a class of enzymes termed “protein kinases.” LRRK2 is frequently mutated in Parkinson’s. Between 1-2 percent of Parkinson’s cases may be caused by mutations in the gene that encodes for the LRRK2 enzyme. To my
Dario Alessi
Medical Research Council Protein Phophorylation and Ubiquitylation UnitUnited Kingdom
Derya Shimshek, Martin Herzig on Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.
COMMENT The exciting findings presented here by Skibinski et al. provide key insights into the cellular role of LRRK2 in neurodegeneration underlying Parkinson’s disease (PD). The authors used a longitudinal, real-time imaging platform to individually track prima
Patrick Verstreken on Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.
COMMENT In this paper, Skibinski et al. use cellular models to assess LRRK2 toxicity. They use automated imaging to assess the time of death of large cohorts of cells and come to the interesting observation that “soluble” LRRK2 levels positively correlate with ea
Rethinking LRRK2 Toxicity: It’s How Much Is Present, Not What It Does
RESEARCH NEWS 2014-01-15 Research News Attempts to discern how mutations in the LRRK2 gene contribute to Parkinson’s disease have focused largely on the protein’s role as a kinase. In the January 8 Journal of Neuroscience, researchers led by Steven Finkbeiner at the Gladstone Ins
Joseph Foss
Cleveland ClinicCleveland, United States
PAPER Xiong Y, Yuan C, Chen R, Dawson TM, Dawson VL
ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2.
J Neurosci. 2012 Mar 14;32(11):3877-86. PubMed: 22423108Alzheimer’s Disease International 2014
CONFERENCE 2014-05-01 00:00:00-2014-05-04 00:00:00 Sheraton Puerto Rico Hotel, San Juan, Puerto Rico 01 May 2014 to 04 May 2014 A captivating programme: Listen to the leading professionals in the field presenting their work and take part in some interactive workshops. You will gain insight into the latest
Matthew Wade
PhD Student
Sarah Shair
PAPER Liu P, Forster C, Kotilinek L, Paulson J, Chen G, Bennett D, Cleary J, Zahs K, Lesné S, Ashe K
Aβ dimers mediate plaque-associated cytopathology without affecting cognition
Alzheimers Dement. 2011 Jul; 7(4 Suppl):e23.Current Filters
No filters selected